OTCMKTS:PFSCF

ProMetic Life Sciences Competitors

$5.47
-0.20 (-3.58 %)
(As of 11/15/2019)
Add
Compare
Today's Range
$5.47
Now: $5.47
$5.47
50-Day Range
$5.47
MA: $5.47
$5.47
52-Week Range
$5.47
Now: $5.47
$352.00
Volume200 shs
Average Volume279 shs
Market Capitalization$127.45 million
P/E RatioN/A
Dividend YieldN/A
Beta2.46

Competitors

ProMetic Life Sciences (OTCMKTS:PFSCF) Vs. AKAOQ, PPCB, COTQF, AOXG, TLOG, and AOLS

Should you be buying PFSCF stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to ProMetic Life Sciences, including Achaogen (AKAOQ), Propanc Biopharma (PPCB), Cotinga Pharmaceuticals (COTQF), Aoxing Pharmaceutical (AOXG), TetraLogic Pharmaceuticals (TLOG), and Aeolus Pharmaceuticals (AOLS).

ProMetic Life Sciences (OTCMKTS:PFSCF) and Achaogen (OTCMKTS:AKAOQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Insider & Institutional Ownership

0.1% of ProMetic Life Sciences shares are owned by institutional investors. Comparatively, 0.0% of Achaogen shares are owned by institutional investors. 7.8% of Achaogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares ProMetic Life Sciences and Achaogen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life Sciences$36.55 million3.49$-150,730,000.00N/AN/A
Achaogen$8.73 million0.15$-186,510,000.00N/AN/A

ProMetic Life Sciences has higher revenue and earnings than Achaogen.

Analyst Ratings

This is a summary of recent ratings and target prices for ProMetic Life Sciences and Achaogen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProMetic Life Sciences0000N/A
Achaogen0000N/A

Volatility and Risk

ProMetic Life Sciences has a beta of 2.46, suggesting that its share price is 146% more volatile than the S&P 500. Comparatively, Achaogen has a beta of -0.84, suggesting that its share price is 184% less volatile than the S&P 500.

Profitability

This table compares ProMetic Life Sciences and Achaogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProMetic Life Sciences-894.02%-3,350.55%-67.76%
AchaogenN/AN/AN/A

Summary

ProMetic Life Sciences beats Achaogen on 5 of the 9 factors compared between the two stocks.

ProMetic Life Sciences (OTCMKTS:PFSCF) and Propanc Biopharma (OTCMKTS:PPCB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Volatility and Risk

ProMetic Life Sciences has a beta of 2.46, meaning that its share price is 146% more volatile than the S&P 500. Comparatively, Propanc Biopharma has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500.

Profitability

This table compares ProMetic Life Sciences and Propanc Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProMetic Life Sciences-894.02%-3,350.55%-67.76%
Propanc BiopharmaN/AN/A-4,812.81%

Earnings and Valuation

This table compares ProMetic Life Sciences and Propanc Biopharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life Sciences$36.55 million3.49$-150,730,000.00N/AN/A
Propanc BiopharmaN/AN/A$-4,740,000.00N/AN/A

Propanc Biopharma has lower revenue, but higher earnings than ProMetic Life Sciences.

Institutional & Insider Ownership

0.1% of ProMetic Life Sciences shares are owned by institutional investors. 0.0% of Propanc Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for ProMetic Life Sciences and Propanc Biopharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProMetic Life Sciences0000N/A
Propanc Biopharma0000N/A

ProMetic Life Sciences (OTCMKTS:PFSCF) and Cotinga Pharmaceuticals (OTCMKTS:COTQF) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, earnings, risk and institutional ownership.

Earnings and Valuation

This table compares ProMetic Life Sciences and Cotinga Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life Sciences$36.55 million3.49$-150,730,000.00N/AN/A
Cotinga PharmaceuticalsN/AN/A$-2,050,000.00N/AN/A

Cotinga Pharmaceuticals has lower revenue, but higher earnings than ProMetic Life Sciences.

Risk & Volatility

ProMetic Life Sciences has a beta of 2.46, meaning that its stock price is 146% more volatile than the S&P 500. Comparatively, Cotinga Pharmaceuticals has a beta of 43.44, meaning that its stock price is 4,244% more volatile than the S&P 500.

Profitability

This table compares ProMetic Life Sciences and Cotinga Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProMetic Life Sciences-894.02%-3,350.55%-67.76%
Cotinga PharmaceuticalsN/AN/AN/A

Insider and Institutional Ownership

0.1% of ProMetic Life Sciences shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for ProMetic Life Sciences and Cotinga Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProMetic Life Sciences0000N/A
Cotinga Pharmaceuticals0000N/A

Summary

Cotinga Pharmaceuticals beats ProMetic Life Sciences on 5 of the 7 factors compared between the two stocks.

ProMetic Life Sciences (OTCMKTS:PFSCF) and Aoxing Pharmaceutical (OTCMKTS:AOXG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Insider and Institutional Ownership

0.1% of ProMetic Life Sciences shares are held by institutional investors. 17.8% of Aoxing Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares ProMetic Life Sciences and Aoxing Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProMetic Life Sciences-894.02%-3,350.55%-67.76%
Aoxing PharmaceuticalN/AN/AN/A

Valuation and Earnings

This table compares ProMetic Life Sciences and Aoxing Pharmaceutical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life Sciences$36.55 million3.49$-150,730,000.00N/AN/A
Aoxing PharmaceuticalN/AN/AN/AN/AN/A

Aoxing Pharmaceutical has lower revenue, but higher earnings than ProMetic Life Sciences.

Analyst Ratings

This is a summary of current ratings and target prices for ProMetic Life Sciences and Aoxing Pharmaceutical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProMetic Life Sciences0000N/A
Aoxing Pharmaceutical0000N/A

Volatility & Risk

ProMetic Life Sciences has a beta of 2.46, indicating that its share price is 146% more volatile than the S&P 500. Comparatively, Aoxing Pharmaceutical has a beta of 3.26, indicating that its share price is 226% more volatile than the S&P 500.

Summary

Aoxing Pharmaceutical beats ProMetic Life Sciences on 5 of the 7 factors compared between the two stocks.

TetraLogic Pharmaceuticals (OTCMKTS:TLOG) and ProMetic Life Sciences (OTCMKTS:PFSCF) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Profitability

This table compares TetraLogic Pharmaceuticals and ProMetic Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TetraLogic PharmaceuticalsN/AN/AN/A
ProMetic Life Sciences-894.02%-3,350.55%-67.76%

Earnings & Valuation

This table compares TetraLogic Pharmaceuticals and ProMetic Life Sciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TetraLogic PharmaceuticalsN/AN/AN/AN/AN/A
ProMetic Life Sciences$36.55 million3.49$-150,730,000.00N/AN/A

TetraLogic Pharmaceuticals has higher earnings, but lower revenue than ProMetic Life Sciences.

Insider & Institutional Ownership

0.1% of ProMetic Life Sciences shares are held by institutional investors. 15.4% of TetraLogic Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for TetraLogic Pharmaceuticals and ProMetic Life Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TetraLogic Pharmaceuticals0000N/A
ProMetic Life Sciences0000N/A

Volatility & Risk

TetraLogic Pharmaceuticals has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, ProMetic Life Sciences has a beta of 2.46, indicating that its share price is 146% more volatile than the S&P 500.

Summary

TetraLogic Pharmaceuticals beats ProMetic Life Sciences on 4 of the 7 factors compared between the two stocks.

ProMetic Life Sciences (OTCMKTS:PFSCF) and Aeolus Pharmaceuticals (OTCMKTS:AOLS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk.

Analyst Ratings

This is a summary of current recommendations and price targets for ProMetic Life Sciences and Aeolus Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProMetic Life Sciences0000N/A
Aeolus Pharmaceuticals0000N/A

Earnings & Valuation

This table compares ProMetic Life Sciences and Aeolus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life Sciences$36.55 million3.49$-150,730,000.00N/AN/A
Aeolus PharmaceuticalsN/AN/AN/AN/AN/A

Aeolus Pharmaceuticals has lower revenue, but higher earnings than ProMetic Life Sciences.

Volatility and Risk

ProMetic Life Sciences has a beta of 2.46, meaning that its stock price is 146% more volatile than the S&P 500. Comparatively, Aeolus Pharmaceuticals has a beta of 2.38, meaning that its stock price is 138% more volatile than the S&P 500.

Insider & Institutional Ownership

0.1% of ProMetic Life Sciences shares are owned by institutional investors. 66.6% of Aeolus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares ProMetic Life Sciences and Aeolus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProMetic Life Sciences-894.02%-3,350.55%-67.76%
Aeolus PharmaceuticalsN/AN/AN/A

Summary

Aeolus Pharmaceuticals beats ProMetic Life Sciences on 4 of the 7 factors compared between the two stocks.


ProMetic Life Sciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Achaogen logo
AKAOQ
Achaogen
0.6$0.03-0.4%$1.29 million$8.73 million0.00Gap Up
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.21-4.5%$1.17 millionN/A0.00Decrease in Short Interest
Gap Up
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05-0.0%$1.12 millionN/A-0.57Upcoming Earnings
Gap Down
AOXG
Aoxing Pharmaceutical
0.5$0.01-13.0%$991,000.00N/A0.00Gap Down
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04-1.3%$978,000.00N/A0.00Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01-3.3%$928,000.00N/A0.00Gap Up
ATRX
Adhera Therapeutics
0.0$0.06-7.1%$872,000.00$250,000.000.00Gap Down
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07-8.1%$865,000.00N/A0.00Gap Up
PXYN
Praxsyn
0.6$0.00-10.0%$763,000.00N/A0.00Gap Down
SPHS
Sophiris Bio
0.1$0.02-0.0%$693,000.00N/A0.00Gap Down
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05-0.0%$572,000.00$1.90 million0.00
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.03-26.0%$547,000.00N/A0.00Gap Down
TRPXD
Therapix Biosciences
0.0$9.20-0.5%$460,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.16-5.6%$399,000.00N/A0.00Gap Up
SKVI
Skinvisible
0.7$0.10-11.6%$376,000.00$40,000.000.00
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01-2.0%$366,000.00N/A0.00Gap Down
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01-0.0%$343,000.00N/A0.00
PZRXQ
PhaseRx
0.2$0.03-35.2%$332,000.00N/A0.00
WDBG
Woodbrook Group
0.0$1.60-0.0%$224,000.00N/A0.00
ROSGQ
Rosetta Genomics
0.0$0.08-21.2%$183,000.00N/A0.00
OREXQ
Orexigen Therapeutics
0.4$0.01-26.4%$100,000.00$33.71 million0.00Gap Up
MetaStat logo
MTST
MetaStat
0.0$0.01-0.7%$82,000.00$20,000.000.00
AXMP
AXM Pharma
0.2$0.00-0.0%$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00-0.0%$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00-0.0%$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.02-3.3%$7,000.00$110,000.000.00Gap Up
Acusphere logo
ACUS
Acusphere
0.0$0.05-2.2%$0.00N/A0.00Gap Down
Affymax logo
AFFY
Affymax
0.6$0.10-17.3%$0.00N/A0.00Gap Down
AOBI
American Oriental Bioengineering
0.4$1.50-0.0%$0.00N/A0.00
ARYX
ARYx Therapeutics
0.0$0.02-67.5%$0.00N/A0.00High Trading Volume
Gap Down
AHROQ
AtheroNova
0.0$0.01-0.0%$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.07-0.0%$0.00N/A0.00Gap Down
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.01-0.0%$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.49-0.0%$0.00$9.93 million8.13
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04-0.0%$0.00N/A0.00
FTCY
Global Future City
0.5$0.00-0.0%$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$32.02-3.9%$0.00N/A0.00Decrease in Short Interest
Gap Up
HRBR
Harbor Diversified
0.0$1.13-13.8%$0.00$263.61 million0.00
IPAH
Interpharm
0.2$0.00-25.0%$0.00N/A0.00Gap Up
IRBS
IR Biosciences
0.0$0.00-0.0%$0.00N/A0.00High Trading Volume
MBVXQ
MabVax Therapeutics
0.0$0.02-8.7%$0.00N/A0.00Gap Up
MYRX
Myrexis
0.5$0.06-0.0%$0.00N/A0.00Gap Up
NNBP
Nanobac Pharmaceuticals
0.0$0.00-0.0%$0.00N/A0.00Gap Down
PARD
Poniard Pharmaceuticals
0.5$0.06-29.1%$0.00N/A0.00High Trading Volume
SGTI
Shengtai Pharmaceutical
0.2$0.02-0.0%$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00-0.0%$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.05-6.1%$0.00$26.09 million0.00Gap Up
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.04-0.0%$0.00N/A0.00
SYNI
Synvista Therapeutics
0.0$0.00-70.0%$0.00N/A0.00Gap Down
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.